Critical Care Medicine
Gastrointestinal Emergencies: Hirschsprung Disease, Congenital Aganglionic Megacolon
Also known as: Congenital Aganglionic Megacolon
1. Description of the problem
Hirschsprung disease (HD) describes a failure of neural crest cell migration to the entire colon during intestinal development. The result is an aganglionic segment of colon that is unable to relax, causing obstruction and the potential for severe complications.
Delay/failure of passage of stools (including meconium)
Chronic constipation in children/adults with low-segment HD.
Rectal biopsy - The gold standard of HD diagnosis is a rectal biopsy, with absent ganglion cells often confirmed by elevated acetylcholinesterase activity in special staining and hypertrophic nerve fibers. Rectal suction biopsy are often sufficient and can be done without general anesthesia. If nondiagnostic, a full-thickness biopsy may be necessary.
Abdominal X-ray - A distal intestinal obstruction with dilated bowel loops often suggests HD and identifies the likely transition zone
Contrast enema - A sharp transition zone often in the recto-sigmoid colon suggests the diagnosis of HD and can help surgeons locate the transition point or suggest the need for a rectal suction biopsy to confirm HD.
Anorectal manometry - especially useful for short-segment HD with the inability to relax the internal anal sphincter with balloon distention of the rectum. If the internal anal sphincter relaxes with balloon distention, HD is excluded.
4. Specific Treatment
Treatment of HD is surgical. If emergent, a colostomy is often necessary prior to a second-stage pull-through. If non-emergent, a one-stage pull-through is possible without a significant increase in the complication rate.
The prognosis or HD after pull-through is excellent, with near-normal anorectal function unless total colonic aganglionosis is present. Fecal incontinence and chronic constipation are the most common long-term complications.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship